can induce a remission in a majority of patients presenting with acute myeloblastic leukemia (AML), a minority fail to respond and moreover the drug has less effect in acute lymphoblastic leukemia (ALL). The carrier-mediated influx of araC into purified blasts from patients with AML, ALL, and acute undifferentiated leukemia (AUL) has been compared to that of normal lymphocytes and polymorphs. Blasts showed a larger mediated influx of araC than mature cells, since mean influxes for myeloblasts and lymphoblasts were 6-and 2.3-fold greater than polymorphs and lymphocytes, respectively. Also, the mean influx for myeloblasts was fourfold greater than the mean for lymphoblasts. The number of nucleoside transport sites was estimated for each cell type by measuring the equilibrium binding of [3H]nitrobenzylthioinosine (NBMPR), which inhibits nucleoside fluxes by binding with high affinity to specific sites on the transport mechanism. The mean binding site numbers for myeloblasts and lymphoblasts were 5-and 2.8-fold greater, respectively, than for the mature cells of the same maturation series. The mean number of NBMPR binding sites for myeloblasts was fourfold greater than for lymphoblasts. Patients with AUL were heterogeneous since blasts from some gave values within the myeloblastic range and others within the lymphoblastic range. The araC influx correlated closely with the number of NBMPR binding sites measured in the same cells on the same day. Transport parameters were measured on blasts from 15 patients with AML or AUL who were then treated with standard induction therapy containing araC. Eight patients entered complete remission, while seven failed therapy, among whom
binding sites for myeloblasts was fourfold greater than for lymphoblasts. Patients with AUL were heterogeneous since blasts from some gave values within the myeloblastic range and others within the lymphoblastic range. The araC influx correlated closely with the number of NBMPR binding sites measured in the same cells on the same day. Transport parameters were measured on blasts from 15 patients with AML or AUL who were then treated with standard induction therapy containing araC. Eight patients entered complete remission, while seven failed therapy, among whom INTRODUCTION First remissions can be induced in approximately half the patients with acute myeloblastic leukemia (AML)' by therapy with drug combinations containing cytosine arabinoside (araC). It is generally considered that the conversion of araC to araCTP is central for the cytotoxic effect of this drug since araCTP is known to inhibit the synthesis of DNA (1) (2) (3) (4) (5) . Resistance of cells to araC has been considered to arise from deficiency in araC phosphorylation by deoxycytidine kinase possibly coupled with increased degradation of araC by cytidine deaminase (6) (7) (8) . However, these enzymatic activities have not proven to be useful predictors of clinical response to araC therapy (9, 10) . Permeation of araC is an essential prerequisite for its metabolic conversions but there is no information on this process in fresh leukemic cells. Movement of nu- cleoside and many of their analogs across the plasma membrane in many cell types is mediated by a nucleoside specific transport mechanism. Cytosine arabinoside is a substrate for this carrier system (11) (12) (13) (14) (15) that is reversible, nonconcentrative, and has a broad specificity for pyrimidine and purine nucleosides. However, the affinity of the nucleoside carrier in leukemic cells is less for araC than for its naturally occurring pyrimidine analog, deoxycytidine. 2 A number of potent inhibitors of nucleoside transport have been identified such as dipyridamole and nitrobenzylthioinosine (NBMPR). These compounds bind with high affinity to specific sites on the exterior of the cell, such that occupancy of these sites by inhibitor blocks nucleoside transport. Several studies suggest that the number of NBMPR binding sites on cell membranes can be equated with the number of functional nucleoside transport sites. Strong evidence comes from work on the genetic polymorphism of nucleosidepermeable or impermeable sheep erythrocytes. Nucleoside-permeable erythrocytes possess high affinity NBMPR binding sites but such sites were absent from erythrocytes lacking capacity for nucleoside transport (16) . Moreover in human erythrocytes a direct proportionality has been shown between the fractional inhibition of uridine transport and the occupancy of the total available NBMPR binding sites (17) .
The present study has examined whether variability in the nucleoside permeability of leukemic blasts may offer an explanation for the resistance of some leukemias to araC. Both the influx of araC as well as the number of NBMPR binding sites have been measured on blasts prepared from fresh peripheral blood. In a group of 15 (21) . Duration of araC infusion was shortened to 5 d for second and subsequent courses (22) . All patients received two or more courses except patient M.F. who declined therapy after 4 d of araC because of intense nausea. Criteria for response were those of the acute leukemia group B (23) . Patients in complete remission were asymptomatic, and had nondiagnostic bone marrow morphology and normal peripheral blood counts. Patients with partial remission were also asymptomatic and had a normal peripheral blood count.
Lymphocyte and blast isolation. Venous blood from healthy subjects (120-180 ml) and leukemic patients (10-30 ml) was defibrinated by shaking with acid-washed glass beads (2 mm Diam) in a stoppered flask. When platelet counts were <10,000/,ul blood was drawn into heparin anticoagulant. Normal blood was diluted with 2 vol saline and incubated with carbonyl-iron (0.5 mg/ml) with slow agitation at 37°C for 40 min to remove phagocytic mononuclear cells (24) . Blasts and lymphocytes were separated by isopyknic sedimentation on a Ficoll-Isopaque gradient at 400 g at 18-20°C for 30 min in polycarbonate tubes. Cells at the interface were harvested and washed thrice in buffered saline.
In some normal lymphocyte preparations erythrocyte contamination was as much as 35% of the total cell count, as quantitated by cell counts with and without saponin (Zaponin; Coulter Electronics, Ltd., Dunstable, England) an erythrocyte lysing agent. Erythrocytes were depleted by cold hypotonic shock lysis of the suspension (25) . To 2 ml cell suspension in isotonic buffered saline were added 6 ml of cold distilled water (yielding 0.25 times isotonicity) followed after 30 s by the rapid addition of 2 ml of 600 mM NaCl to restore isotonicity. Leukocytes were separated from hemolyzed material by centrifugation at 150 g for 5 min followed by aspiration of erythrocyte ghosts on the surface of the leukocyte layer. After two such treatments the final erythrocyte contamination was always <5-10% of the total cell count.
Polymorphonuclear leukocyte preparation. Venous blood (60-180 ml) from normal donors was defibrinated, mixed with 0.1 vol 4% dextran T500 in 150 mM NaCl, and left to stand at 18-20°C for 60-75 min. The supernate contained mainly leukocytes, and was centrifuged over a Ficoll-Isopaque density gradient as above. The cell pellet of polymorphs was resuspended in 2 ml of imidazole-buffered saline and residual erythrocytes lysed by the addition of 18 ml icecold water for 30 s, followed by restoration of isotonicity with 20 ml 300 mM NaCl. Polymorphs were washed thrice in buffered saline.
Cell suspensions. Cells were suspended at 0.5-2.5 X 107 cells/ml in imidazole-buffered saline. Cell counts were performed on a Coulter model DN electronic particle counter with a 100-Am orifice. Homogeneity and cell morphology were checked on a cytocentrifuge preparation for each experiment. Normal lymphocyte preparations contained 95±2% (SD) lymphocytes, 3±1% monocytes and 2±1% polymorphs (24) , while acute leukemic preparations always contained >95% blasts.
Measurement of [3H]araC influx. The cell suspension (1.2 ml) was incubated in stoppered plastic tubes at 20.0°C for 5 min, [3H]araC (5-180 MM) added at zero time and the suspension gently agitated. In some experiments samples (1.0 ml) were removed at 30 s and added to microfuge tubes containing 0.1 ml 20 AM NBMPR, to stop any further cell uptake of labeled nucleoside ("inhibitor-stop" technique). Phthalate oil mix (0.3 ml) was added and the cells centrifuged under the oil layer in an Eppendorf microcentrifuge at 8,000g for 4 min. In other experiments samples were removed and the influx was terminated at 30 s by simply centrifuging the cells through the phthalate-oil mixture ("oil-stop" technique). The supernatant above the oil interface was sampled and counted to determine the concentration of araC. The remainder of the supernatant was aspirated, the walls of the microfuge tubes washed thrice with H20, and most of the oil removed with the final washing. Cell pellets were solubilized in 0.5 ml 0.5 N NaOH, scintillation fluid added and the vial contents were acidified and Kinetic and Scatchard analyses. The kinetics of facilitated influx of araC into leukocytes and blasts was well-described by a Michaelis-Menten treatment. The kinetic data were analyzed by means of plots of S/V vs. S and of V vs. V/S to which linear regression lines were fitted. Concordance was observed between estimates of the kinetic parameters from the two methods that were used to calculate araC influx at 1 MM extracellular concentration (V 1 MuM).
The specific binding of [3H]NBMPR was analyzed by Scatchard plots as described by Edsall and Wyman (28) and the maximum number of binding sites per cell was obtained by extrapolation of the regression line to the abscissa, while the dissociation constant (Kd) was the reciprocal of the association constant given by the slope of the regression line.
Intracellular water space. Cell suspensions were incubated for 5 min at 370C with 3H20 (5 MCi/ml) and aliquots layered over phthalate oil mix, and centrifuged at 8,000 g for 4 min. The trapped extracellular space was determined with [3H]sucrose in parallel tubes. Cell pellets were counted and intracellular water space calculated (29) .
Statistics. Mean values±1 SD are shown unless otherwise stated and the significance of differences between means were analyzed by a Student's t test. Regression lines were fitted by the method of least squares.
RESULTS
AraC uptake over short time intervals. Analysis of nucleoside influx is only valid if the initial rates of araC uptake into cells is determined. The uptake of araC into blasts incubated with 1 zM araC for 10-60 s at 20°C was measured using an "inhibitor-stop" technique. Total uptake of nucleoside was linear with incubation time to 60 s and the nonfacilitated component, defined by the uptake in the presence of 3 ,M NBMPR was <22% of the total uptake (Fig. 1) (Fig. 3) . Analysis yielded linear Scatchard plots suggesting that the inhibitor interacts with a single class of binding site (Fig.  4) binding sites on blasts and either intracellular water space (r = 0.68; P < 0.02) or the minimum surface area of the cell3 calculated from this intracellular water space (r = 0.67; P < 0.05). Thus the size of a cell or its surface area may be factors that contribute to the large variability in NBMPR binding site numbers between different blast types.
Relation of clinical response to araC influx. Transport parameters for araC were studied in 15 patients at presentation who were then comnmenced on standard induction therapy with 7 d of continuous araC plus three daily doses of daunorubicin (21, 22) . Eight patients achieved complete remission while another five failed, despite completing two or more courses of the combination containing araC. Two patients reached partial remission, one after two courses and another (M.F.) after only 4 d of araC although she then declined further treatment because of nausea. The three patients with araC influx into their peripheral blood blasts of <0.4 pmol/107 cells per min all failed induction therapy (Fig. 7) . The number of NBMPR binding sites on blasts from two of these three patients (P.B. and E.L.) was 2,540 and 2,040 sites/cell, respectively, which were the lowest site densities among the treated patients. Binding of NBMPR to blasts from the third patient was not measured. The other two patients who QT.M. (31) . The wide scatter of influx values between individuals was observed both for total araC uptake rates as well as for the NBMPR-sensitive component of araC uptake (influx) that occurs via a facilitated transport mechanism and is the major route by which nucleoside enters the cell. Despite the variability in influx between different cell preparations, the NBMPR-sensitive component of araC uptake always accounted for a relatively constant (78-89%) proportion of the total araC entry rate with 1 ,uM external araC concentration. Thus leukemic blasts resemble HeLa and other cultured cells in which the major route of nucleoside entry is by a facilitated diffusion system (26, 27) . Why is nucleoside transport greater in immature blasts than in the end product cells of differentiation? The proliferative rate of blasts is clearly greater than their mature descendents and it is known that several membrane transport processes are greater for cells in active division compared with their quiescent counterparts. Both active K+ influx and the number of cation pumps increase fourfold after stimulation of 3T3 cells into proliferation with serum, while glucose and phosphate transport rates are also elevated under the same conditions (32, 33) . The high araC influx of proliferating blasts could result either from a greater number of nucleoside carriers or a higher turnover rate of each carrier and these two possibilities were studied. Equilibrium binding studies of NBMPR to intact cells allows the nucleoside-transport elements in the cell membrane to be directly enumerated (34) . Lymphoblasts possessed 2.8-fold more NBMPR binding sites than lymphocytes, while myeloblasts had fivefold more binding sites than polymorphs. A mixed population of promyelocytes, myelocytes, and metamyelocytes had a mean value for NBMPR binding that was intermediate between myeloblasts and polymorphs. Thus, a high number of NBMPR binding sites is a general characteristic of immature blasts and their immediate descendents compared with the more mature counterparts in the sequence of myeloid and lymphoid differentiation. However, myeloblasts had fourfold more binding sites than lymphoblasts and this finding cannot be attributed to differences in maturity or state of cell differentiation. Also, AUL showed a mean binding site density intermediate between the values for myeloblasts and lymphoblasts. Is the higher proliferative rate of blasts a likely explanation for their greater density of NBMPR binding sites? Many types of cultured neoplastic cells of both human and mouse origin have been studied with respect to the density of NBMPR binding sites ( Table I ). All of the cultured (Table I ). The growth fraction of leukemic cells is generally considered <1.0 and recent estimates based on nuclear DNA-polymerase activity suggest that less than half the leukemic blasts of marrow are in active proliferation (35, 36) . Moreover the growth fraction of blasts from peripheral blood may be still lower, since tritiated thymidine labeling indices are considerably less for circulating than for intramedullary blasts (37, 38 It is established that araC is a substrate for the nucleoside-specific transport mechanism in the cell membrane (12) (13) (14) 39) so that transport rate of araC should relate to the density of transport elements in the cell membrane. The validity of this concept is apparent in the correlation of Fig. 6 between NBMPR-binding site density and araC influx rate at 1-MuM concentration of nucleoside, the latter concentration being chosen to approximate the serum levels achieved during araC infusion to leukemic patients (30) . Recent genetic evidence also indicates a link between nucleoside transport rate and the number of NBMPR binding sites. Nucleoside transport in sheep erythrocytes is a polymorphic character under the control of two allelic genes (40) . Some sheep have erythrocytes with nucleoside transport capability as well as specific NBMPRbinding sites, whereas such sites were absent from other sheep whose erythrocytes were impermeable to nucleosides (16 One aim of this study was to find whether araC influx relates to the clinical response of acute nonlymphoblastic leukemia to araC. A wide variation in transport capacity of blasts from various patients with AML or AUL is evident both in Fig. 2 and 5. 15 of these patients were treated with chemotherapy and 8 entered complete remission while 7 failed therapy. The results in Fig. 7 show that three patients with a low araC influx into blasts (<0.4 pmol/107 cells per min) or few NBMPR binding sites (<3,000/blast) were among the treatment failures. Remission induction with two or three cycles of combination therapy containing araC was ineffective in eliminating either the peripheral or bone marrow blasts from these three patients, all of whom were typed as AUL by cytochemistry. It should be cautioned that araC transport parameters were measured on blasts from peripheral blood, while the clinical response of patients is determined by the effect of araC on blasts in the marrow. Intramedullary blasts differ from circulating blasts in having a much higher tritiated thymidine labeling index (37, 38) ; and greater mitotic activity of marrow blasts may confer higher transport capacity on these cells (see above). Nevertheless, peripheral blood blasts that are easy to obtain and purify may still yield data of predictive value.
Is the influx rate of araC measured over 30 s relevant to the cytotoxic effect of this drug given by constant infusion for 7 d? Clearly much depends on whether the araC that enters the cell is immediately converted to its active metabolite, araCTP. An analysis of nucleoside uptake in fibroblasts has shown that when membrane transport of high capacity and low affinity is followed by a trapping step (kinase) of low capacity and high affinity then at very low nucleoside concentrations, much of the solute that enters is trapped immediately (15) . Indeed, Ho et al. (48) found negligible amounts of free intracellular araC when leukemic blasts and normal leukocytes were incubated in vitro with low concentrations of araC (0.4-4 gM). Thus membrane transport of araC at the concentrations achieved therapeutically in plasma (0.3-1.1 ,M) could be one rate-limiting step for the formation of araCTP in the leukemic blasts possessing low transport capacity. Support for this possibility comes from "protection" experiments. Animals can be protected against the lethal effect of cytotoxic nucleosides by NBMPR, a transport inhibitor whose sole action is to prevent the entry of nucleoside into the cell (49) . Moreover the inhibitory effect of araC on growth of cultured leukemic cells can be reversed by NBMPR or by dipyridamole, which is another inhibitor of nucleoside transport (50, 51) . Cultured lymphoid cells in which nucleoside transport is impaired by mutation can also survive when exposed to potentially lethal doses of cytotoxic nucleosides (52) . Clearly in all these situations a low rate of araC transport confers protection against the cytotoxic effect of this drug. Rustum and Preisler (53) have recently reported that in some 15% of patients with acute nonlymphoblastic leukemia, the bone marrow blasts could not convert extracellular araC to intracellular araCTP. It is not known whether this failure of leukemic cells to metabolize araC is related to low membrane transport of the nucleoside such as seen in some of our patients.
Although a low araC influx may predict a poor response to drug therapy, the converse is not necessarily true. Four of the 10 patients whose blasts gave an araC influx >1.0 pmol/107 cells per min failed to achieve a complete remission although two of the four failures did achieve partial remission. It should be recognized that the hazards of combination chemotherapy and its associated cytopenias make complete remisson of the patient an imprecise measure of the cytotoxic effect of araC on blasts. This is illustrated by the failure of two patients to achieve remission because of side effects of therapy. Patient M.F. refused further treatment after achieving partial remission because of intense nausea from araC while patient V.P. developed irreversible nephrotoxicity during gentamycin therapy for infection. Thus, a larger series of patients will be needed to find if a high araC influx predicts for clinical response to the drug. Nevertheless it seems clear that tests such as araC retention by blasts (1) or measurement of araC transport rates such as in this study will have value in predicting a poor response of certain patients to chemotherapy.
